{"id":"sertraline-olanzapine","safety":{"commonSideEffects":[{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Sexual dysfunction"},{"rate":null,"effect":"Metabolic syndrome"},{"rate":null,"effect":"Akathisia"}]},"_chembl":{"chemblId":"CHEMBL3989694","moleculeType":"Small molecule","molecularWeight":"718.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sertraline is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking its reuptake transporter. Olanzapine is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors. This combination targets both serotonergic and dopaminergic pathways to address mood and psychotic symptoms.","oneSentence":"Sertraline inhibits serotonin reuptake while olanzapine blocks dopamine and serotonin receptors, together providing antidepressant and antipsychotic effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:07:39.615Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder with psychotic features"},{"name":"Treatment-resistant depression"}]},"trialDetails":[{"nctId":"NCT05814640","phase":"PHASE1, PHASE2","title":"Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-02-20","conditions":"Depression, Sequestra","enrollment":520},{"nctId":"NCT04478526","phase":"NA","title":"Efficacy of Online CBT for GAD Compared to Pharmaceutical Interventions","status":"COMPLETED","sponsor":"Dr. Nazanin Alavi","startDate":"2020-04-29","conditions":"Generalized Anxiety Disorder","enrollment":115},{"nctId":"NCT06357104","phase":"PHASE4","title":"Detoxification From the Lipid Tract","status":"COMPLETED","sponsor":"Pachankis, Yang I., M.D.","startDate":"2024-02-26","conditions":"COVID-19 Vaccine Adverse Reaction","enrollment":1},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT06035003","phase":"NA","title":"Mechanism of Mindfulness-Based Online Intervention in Enhancing Cognitive Flexibility","status":"UNKNOWN","sponsor":"Peking University","startDate":"2023-09-18","conditions":"Emotional Distress","enrollment":595},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT05891015","phase":"NA","title":"The Mechanism of Mindfulness Intervention to Alleviate Emotional Distress in Patients With Emotional Disorders","status":"UNKNOWN","sponsor":"Peking University","startDate":"2023-06-20","conditions":"Emotional Distress, Emotional Disorder","enrollment":200},{"nctId":"NCT05833399","phase":"","title":"Correlation of Genetic Variations With Clinical Response in Substance Use Disorder","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-11-28","conditions":"Substance Use Disorders, Substance Dependence","enrollment":200},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT05606224","phase":"NA","title":"The Effects and Mechanisms of Mindfulness Intervention for Emotional Distress","status":"UNKNOWN","sponsor":"Peking University","startDate":"2022-02-20","conditions":"Emotional Disorder","enrollment":200},{"nctId":"NCT05600790","phase":"NA","title":"Mechanism of Mindfulness Based Online Intervention in Reducing Emotional Distress","status":"UNKNOWN","sponsor":"Peking University","startDate":"2022-10-29","conditions":"Emotional Distress","enrollment":300},{"nctId":"NCT04076371","phase":"NA","title":"The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Beijing HuiLongGuan Hospital","startDate":"2012-01","conditions":"Schizophrenia","enrollment":1640},{"nctId":"NCT01427608","phase":"PHASE4","title":"Sustaining Remission of Psychotic Depression","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2011-10","conditions":"Psychotic Depression","enrollment":269},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT01305707","phase":"PHASE4","title":"Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression","status":"TERMINATED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2009-07","conditions":"Depression","enrollment":104},{"nctId":"NCT00056472","phase":"PHASE3","title":"Study of Pharmacotherapy of Psychotic Depression","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2003-01","conditions":"Major Depressive Disorder With Psychotic Features","enrollment":259},{"nctId":"NCT00704860","phase":"PHASE4","title":"Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism","status":"COMPLETED","sponsor":"University of Ottawa","startDate":"2005-02","conditions":"Major Depression","enrollment":27},{"nctId":"NCT01000402","phase":"PHASE4","title":"Juvenile Bipolar Disorder Outpatient Program","status":"UNKNOWN","sponsor":"Federal University of Rio Grande do Sul","startDate":"2008-02","conditions":"Bipolar Disorder, Attention Deficit Disorder With Hyperactivity","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zyprexa"],"phase":"marketed","status":"active","brandName":"Sertraline + Olanzapine","genericName":"Sertraline + Olanzapine","companyName":"Weill Medical College of Cornell University","companyId":"weill-medical-college-of-cornell-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sertraline inhibits serotonin reuptake while olanzapine blocks dopamine and serotonin receptors, together providing antidepressant and antipsychotic effects. Used for Major depressive disorder with psychotic features, Treatment-resistant depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}